Search Results - "Burciu, Alis"

Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry.

Authors: Correll, Colleen Burciu, Alis Bansal, Amita et al.

Source: Pediatric Rheumatology. 10/21/2025, Vol. 23 Issue 1, p1-10. 10p.

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria.

Authors: Gimenez‐Arnau, Ana M. Maurer, Marcus Reich, Adam et al.

Source: Allergy. Jul2026, Vol. 81 Issue 7, p2391-2402. 12p.

Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.

Authors: Ji, Yan Calonder, Claudio Kirsilä, Tiina et al.

Source: Pharmaceutics. Sep2023, Vol. 15 Issue 9, p2266. 13p.

Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.

Authors: Staubach, Petra Alvaro‐Lozano, Montserrat Sekerel, Bulent Enis et al.

Source: Pediatric Allergy & Immunology. Jul2023, Vol. 34 Issue 7, p1-11. 11p.

Long term safety and efficacy of ligelizumab in the treatment of Japanese patients with chronic spontaneous urticaria.

Authors: Takahashi, Hidetoshi Fukunaga, Atsushi Hayama, Koremasa et al.

Source: Allergology International. Jan2025, Vol. 74 Issue 1, p136-143. 8p.

Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study.

Authors: Maurer, Marcus Giménez‐Arnau, Ana Bernstein, Jonathan A. et al.

Source: Allergy. Jul2022, Vol. 77 Issue 7, p2175-2184. 10p.

Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria.

Authors: Ji Y Calonder C Kirsiläe T et al.

Source: Clinical and translational science [Clin Transl Sci] 2026 Jul; Vol. 19 (7), pp. e70661.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III

Journal Info: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE

Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials.

Authors: Giménez-Arnau AM Zharkov A Yang B et al.

Source: The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2026 Jun 03. Date of Electronic Publication: 2026 Jun 03.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101597220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2201 (Electronic) NLM ISO Abbreviation: J Allergy Clin Immunol Pract Subsets: MEDLINE

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.

Authors: Maurer M Ensina LF Gimenez-Arnau AM et al.

Corporate Authors: Maurer M Ensina LF Gimenez-Arnau AM et al.

Source: Lancet (London, England) [Lancet] 2024 Jan 13; Vol. 403 (10422), pp. 147-159. Date of Electronic Publication: 2023 Nov 23.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

Authors: Hiddemann W Barbui AM Canales MA et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 Aug 10; Vol. 36 (23), pp. 2395-2404. Date of Electronic Publication: 2018 Jun 01.

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE